Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.

Kylie N BarnesClaire M VoglLeigh Anne Nelson

Published in: The Annals of pharmacotherapy (2023)

The recent FDA approval of oral zuranolone for PPD offers a second rapid-acting treatment for PPD, extending the opportunity for treatment to patients in the outpatient setting.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
depressive symptoms
prognostic factors
physical activity